Planet Briefing

First published · Last updated

Long-acting IL-7 (NT-I7, efineptakin alfa) After CD19 CAR T-cell Therapy for Large B-cell Lymphoma: A Phase Ib Trial

Journal article reporting a Phase Ib trial of long-acting IL-7 (NT-I7, efineptakin alfa) after CD19 CAR T‑cell therapy for large B‑cell lymphoma. Publisher listed as Elsevier BV; publication date 2026-09-01.

Categories: public-health, science-and-space

Generated scores

Scores are based on the cited reporting and use a 1–10 scale. Read the methodology.

Confidence
5/10
Geographic reach
1/10
Global importance
2/10
Impact magnitude
2/10
Positivity
5/10
Urgency
1/10

Why it matters

Presents early-phase clinical trial data relevant to post–CAR T‑cell therapy treatment in large B‑cell lymphoma.

Sources

Report an issue